Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
Claas H HinzeDirk FoellAnne L JohnsonSteven J SpaldingBeth S GottliebPaula W MorrisYukiko KimuraKaren OnelSuzanne C LiAlexei A GromJanalee TaylorHermine I BrunnerJennifer L HugginsJames J NoctonKathleen A HainesBarbara S EdelheitMichael ShishovLawrence K JungCalvin B WilliamsMelissa S TesherDenise M CostanzoLawrence S ZemelJason A DareMurray H PassoKaleo C EdeJudyann C OlsonElaine A CassidyThomas A GriffinLinda Wagner-WeinerJennifer E WeissLarry B VoglerKelly A Rouster-StevensTimothy BeukelmanRandy Q CronDaniel KietzKenneth SchiklerJay MehtaTracy V TingJames W VerbskyAnne B EberhardBin HuangEdward H GianniniDaniel J LovellPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Serum S100 levels did not predict maintenance of clinically inactive disease or occurrence of disease flare in patients with polyarticular-course JIA, and S100A12 levels were only moderately, and inversely, correlated with the time to disease flare.